



LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA:

la multidisciplinarietà ottimizza il risultato

29 OTTOBRE 2021

NAPOLI Hotel Royal Continental

MALATTIA «ADVANCED STAGE»: IL RUOLO DELLA TERAPIA DIRETTA ALLA CUTE



UNIVERSITÀ
DEGLI STUDI
FIRENZE

Nicola Pimpinelli



Dipartimento Scienze della Salute – sez. Dermatologia, *Università degli Studi di Firenze*
SS.CC. Dermatologia Firenze, *Azienda USL Toscana Centro*

Dichiarazione conflitto di interessi

Nicola Pimpinelli dichiara di aver intrattenuto rapporti con le seguenti aziende farmaceutiche negli ultimi 2 anni:

ALMIRALL, HELSINN, KYOWA KIRIN, MSD, NOVARTIS,
PIERRE FABRE, RECORDATI RARE DISEASES, SANOFI,
TAKEDA



PATCH STAGE



PLAQUE STAGE



ERYTHRODERMA



TUMOR STAGE



Time Course, Clinical Pathways, and Long-Term Hazards Risk Trends of Disease Progression in Patients With Classic Mycosis Fungoides

A Multicenter, Retrospective Follow-Up Study From the Italian Group of Cutaneous Lymphomas

Pietro Quaglino, MD¹; Nicola Pimpinelli, MD²; Emilio Berti, MD³; Piergiacomo Calzavara-Pinton, MD⁴;
Giuseppe Alfonso Lombardo, MD⁵; Serena Rupoli, MD⁶; Mauro Alaibac, MD⁷; Ugo Bottoni, MD^{8,9}; Angelo Carbone, MD¹⁰;
Paolo Fava, MD¹; Michele Fimiani, MD¹¹; Angela Maria Mamusa, MD¹²; Stefano Titli, MD¹; Pier Luigi Zinzani, MD¹³;
Maria Grazia Bernengo, MD¹; and On behalf of the Gruppo Italiano Linfomi Cutanei (GILC)

G ITAL DERMATOL VENEREOL 2012;147:523-31

**Mycosis fungoides:
disease evolution of the “lion queen” revisited**

P. QUAGLINO¹, N. PIMPINELLI², E. BERTI³, P. CALZAVARA-PINTON⁴, G. A. LOMBARDO⁵, S. RUPOLI⁶,
M. ALAIBAC⁷, L. ARCAINI⁸, S. BAGNATO⁹, A. BALDO¹⁰, U. BOTTONI¹¹, A. CARBONE¹², R. CESTARI¹³,
R. CLERICO¹⁴, A. DE RENZO¹⁵, P. FAVA¹, M. T. FIERRO¹, R. FILOTICO¹⁶, M. FIMIANI¹⁷, M. FRONTANI⁵,
V. GIRGENTI¹⁸, G. GOTERI¹⁹, C. LEALI⁴, A. M. MAMUSA²⁰, G. MARIOTTI², V. MASTRANDREA²¹,
C. PELLEGRINI²², E. PENNESE²³, A. PILERI²⁴, P. SAVOIA¹, C. STELITANO²⁵, S. TITLI¹,
A. VIRGILI²⁶, L. ZICHICHI²⁷, P. L. ZINZANI²², M. G. BERNENGO¹

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO






Figure 3.—Old and new potential disease evolution pathway interpretations.

Figure 2. T score evolution of patients with (a) T1 lesions and (b) T2 lesions at the time of initial diagnosis is shown. The number represents the percentage of patients who developed disease progression calculated based on the total number of patients whose disease progressed from either T1 or T2. Gray-shaded areas at the left of each figure include those patients whose cutaneous disease evolution spared ≥ 1 consecutive stages. The thickness of each line is proportional to the number of patients who developed disease progression after this specific evolution.

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Elise Olsen,¹ Eric Vonderheid,² Nicola Pimpinelli,³ Rein Willemze,⁴ Youn Kim,⁵ Robert Knobler,⁶ Herschel Zackheim,⁷ Madeleine Duric,⁸ Teresa Estrach,⁹ Stanford Lamberg,² Gary Wood,¹⁰ Reinhard Dummer,¹¹ Annamari Ranki,¹² Gunter Burg,¹¹ Peter Heald,¹³ Mark Pittelkow,¹⁴ Maria-Grazia Bemengo,¹⁵ Wolfram Sterry,¹⁶ Lillane Laroche,¹⁷ Franz Trautinger,⁸ and Sean Whittaker,¹⁸ for the ISCL/EORTC

¹Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC; ²Department of Dermatology, Johns Hopkins University, Baltimore, MD; ³Department of Dermatological Sciences, University of Florence, Florence, Italy; ⁴Department of Dermatology, Liden University Medical Center, Liden, The Netherlands; ⁵Department of Dermatology, Stanford University Medical Center, Stanford, CA; ⁶Department of Dermatology, University of Vienna, Vienna, Austria; ⁷Department of Dermatology, University of California at San Francisco; ⁸Department of Dermatology, University of Texas at Houston; ⁹Department of Dermatology, University of Barcelona, Barcelona, Spain; ¹⁰Department of Dermatology, University of Wisconsin, Madison; ¹¹Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; ¹²Department of Dermatology and Venereal Diseases, Helsinki University Hospital, Helsinki, Finland; ¹³Department of Dermatology, Yale University, New Haven, CT; ¹⁴Department of Dermatology, Mayo Clinic, Rochester, MN; ¹⁵Department of Dermatology, University of Turin, Turin, Italy; ¹⁶Department of Dermatology, Charité, Humboldt University, Berlin, Germany; ¹⁷Department of Immuno-Dermatology, Hospital Avicenne-University of Paris XIII, Paris, France; ¹⁸St John's Institute of Dermatology, Skin Tumour Unit, St Thomas' Hospital, London, United Kingdom

The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain

variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision per-

tains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions. (Blood. 2007;110:1713-1722)

© 2007 by The American Society of Hematology

Table 4. ISCL/EORTC revision to the classification of mycosis fungoides and Sézary syndrome

TNMB stages	
Skin	
T ₁	Limited patches,* papules, and/or plaques† covering < 10% of the skin surface. May further stratify into T _{1a} (patch only) vs T _{1b} (plaque ± patch).
T ₂	Patches, papules or plaques covering ≥ 10% of the skin surface. May further stratify into T _{2a} (patch only) vs T _{2b} (plaque ± patch).
T ₃	One or more tumors‡ (≥ 1-cm diameter)
T ₄	Confluence of erythema covering ≥ 80% body surface area
Node	
N ₀	No clinically abnormal peripheral lymph nodes§; biopsy not required
N ₁	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN _{0,2}
N _{1a}	Clone negative#
N _{1b}	Clone positive#
N ₂	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN ₃
N _{2a}	Clone negative#
N _{2b}	Clone positive#
N ₃	Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN ₄ ; clone positive or negative
N _x	Clinically abnormal peripheral lymph nodes; no histologic confirmation
Visceral	
M ₀	No visceral organ involvement
M ₁	Visceral involvement (must have pathology confirmation¶ and organ involved should be specified)
Blood	
B ₀	Absence of significant blood involvement: ≤ 5% of peripheral blood lymphocytes are atypical (Sézary) cells
B _{0a}	Clone negative#
B _{0b}	Clone positive#
B ₁	Low blood tumor burden: > 5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B ₂
B _{1a}	Clone negative#
B _{1b}	Clone positive#
B ₂	High blood tumor burden: ≥ 1000/μL Sézary cells with positive clone#



LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO



LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejancer.com



Review

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017



Franz Trautinger ^{a,b,*}, Johanna Eder ^{a,b}, Chalid Assaf ^c, Martine Bagot ^d, Antonio Cozzio ^e, Reinhard Dummer ^f, Robert Gniadecki ^{g,h}, Claus-Detlev Klemke ⁱ, Pablo L. Ortiz-Romero ^j, Evangelia Papadavid ^k, Nicola Pimpinelli ^l, Pietro Quaglino ^m, Annamari Ranki ⁿ, Julia Scarisbrick ^o, Rudolf Stadler ^p, Liisa Väkevä ⁿ, Maarten H. Vermeer ^q, Sean Whittaker ^r, Rein Willemze ^q, Robert Knobler ^s

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO

Stage IIB

Recommendations for first-line treatment of MF stage IIB.

Systemic therapies ^a	
Retinoids ^b	Level 2
IFN- α	Level 2
TSEB	Level 2
Monochemotherapy	Level 4
(gemcitabine, pegylated liposomal doxorubicine)	
Low dose MTX	Level 4
Localised RT ^c	Level 4

Recommendations for second-line treatment of MF stage IIB.

Polychemotherapy ^a	level 3
Allogeneic stem cell transplantation ^b	level 3

^a CHOP is the most widely used regimen with a number of variants and other combinations available.

^b Should be restricted to exceptional patients, see text for details.

Stage IIIA/B

Recommendations for first-line treatment of MF stage IIIA and B.

Systemic therapies ^a	
Retinoids ^b	Level 2
IFN- α	Level 2
ECP ^c	Level 3
Low dose MTX	Level 4
TSEB	Level 2

Recommendations for second-line treatment of MF stage IIIA and B.

Monochemotherapy (gemcitabine, pegylated liposomal doxorubicine)	Level 3
Allogeneic stem cell transplantation ^a	Level 3

^a Should be restricted to exceptional patients, see text for details.

MF/SS THERAPY AT A GLANCE: FIRST LINE

European Organisation for Research and Treatment of Cancer
consensus recommendations for the treatment of mycosis
fungoides/Sézary syndrome - Update 2017.

F. Trautinger, J. Eder, C. Assaf, M. Bagot, A. Cozzio, R. Dummer, R. Gniadecki, C.D. Klemke, P.L. Ortiz-Romero, E. Papadavid, N. Pimpinelli, P. Quaglino, A. Ranki, J. Scarisbrick, R. Stadler, L. Väkevã, M.H. Vermeer, S. Whittaker, R. Willemze, R. Knobler

European Journal of Cancer (2017) 77: pp57-74

CORTESIA Prof. P. Quaglino



	Wait & see	Topical steroids	Photo therapy	Local RT	TSET	Interferon	Bexarotene	Mono-CT	MTX	PoliCT	ECP
IA	Green	Green	Green	Green							
IB	Green	Green	Green	Green							
IIA		Green	Green	Green							
IIB				Green	Green	Green	Green	Green	Green		
III					Green	Green	Green		Green		Green
SS						Green	Green	Green	Green		Green
IVA - IVB								Green		Green	

MF/SS THERAPY AT A GLANCE: SECOND LINE

CORTESIA Prof. P. Quaglino

European Organisation for Research and Treatment of Cancer
consensus recommendations for the treatment of mycosis
fungoides/Sézary syndrome - Update 2017.

F. Trautinger, J. Eder, C. Assaf, M. Bagot, A. Cozzio, R. Dummer, R. Gniadecki, C.D. Klemke, P.L. Ortiz-Romero, E. Papadavid, N. Pimpinelli, P. Quaglino, A. Ranki, J. Scarisbrick, R. Stadler, L. Väkevã, M.H. Vermeer, S. Whittaker, R. Willemze, R. Knobler

European Journal of Cancer (2017) 77: pp57-74




	Topical steroids	Photo therapy	Local RT	TSET	Interferon	Bexarotene	Mono-CT	MTX	PoliCT	ECP	HSCT
IA					■	■		■			
IB				■	■	■		■			
IIA				■	■	■		■			
IIB									■		■
III							■		■		■
SS							■		■		■
IVA - IVB											■

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO

TREATMENT DOWN GRADE



CORTESIA Prof. P. Quaglino




LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

4 OTTOBRE 2021 - MILANO



The re-challenge paradigm of CTCL therapy

CORTESIA Prof. P. Quaglino



PROCLIFI is an international prospective database in which all the new cases of mycosis fungoides(MF)/Sézary syndrome are registered after central clinico-pathological review to confirm diagnosis.


PROCLIFI



PROCLIFI STUDY FOR MYCOSIS FUNGOIDES & SEZARY SYNDROME

PROspective Cutaneous Lymphoma International Prognostic Index

Leader : JJ Scarisbrick (UK), Youn Kim (Stanford)



GENERAL DERMATOLOGY

BJD
British Journal of Dermatology

The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

J.J. Scarisbrick^{1,2,3,4}, P. Quaglino^{5,6}, H.M. Prince⁷, E. Papadavid^{8,9}, E. Hodak^{10,11}, M. Bagot^{12,13}, O. Servitje^{14,15}, E. Berti^{16,17}, P. Ortiz-Romero^{18,19}, R. Stadler^{20,21}, A. Patsatsi^{22,23}, R. Khobler^{24,25}, E. Guenova^{26,27}, F. Chiles^{28,29}, S. Whittaker^{30,31}, V. Nkololou^{32,33}, C. Tomasini^{34,35}, I. Amity^{36,37}, K. Prag Naveh^{38,39}, C. Ram-Wolf^{40,41}, M. Battistella^{42,43}, S. Alberti-Violetti^{44,45}, R. Stranzbach^{46,47}, V. Gargallo^{48,49}, C. Muniesa^{50,51}, T. Koletsa^{52,53}, C. Jonak^{54,55}, S. Parkert^{56,57}, C. Mitteldorf^{58,59}, T. Estrach^{60,61}, A. Camballa^{62,63}, M. Marschallko^{64,65}, J. Csomor^{66,67}, A. Szepesi^{68,69}, A. Cozzio^{70,71}, R. Dummer^{72,73}, N. Pimpinelli^{74,75}, V. Grandi^{76,77}, M. Beylot-Barry^{78,79}, A. Pham-Ledard^{80,81}, M. Wobser^{82,83}, E. Geislinger^{84,85}, U. Wehkamp^{86,87}, M. Weichenath^{88,89}, R. Cowan^{90,91}, E. Parry^{92,93}, J. Harris^{94,95}, R. Wachsmuth^{96,97}, D. Turner^{98,99}, A. Bates^{100,101}, E. Healy^{102,103}, F. Trautinger^{104,105}, J. Latzka^{106,107}, J. Yoo^{108,109}, B. Vydianath^{110,111}, R. Amel-Kashipaz^{112,113}, L. Marinou^{114,115}, A. Oikonomidi^{116,117}, A. Stratigos^{118,119}, M.-D. Vignon-Pennamen^{120,121}, M. Battistella^{122,123}, F. Climent^{124,125}, E. Gonzalez-Barca^{126,127}, E. Georgiou^{128,129}, R. Senetta^{130,131}, P. Zinzani^{132,133}, L. Vakeva^{134,135}, A. Ranki^{136,137}, A.-M. Busschots^{138,139}, E. Hauben^{140,141}, A. Bervoets^{142,143}, F.J.S.H. Woei-A-jin^{144,145}, R. Matin^{146,147}, G. Collins^{148,149}, S. Weatherhead^{150,151}, J. Frew^{152,153}, M. Bayne^{154,155}, G. Dunning^{156,157}, P. McKay^{158,159}, A. Arumainathan^{160,161}, R. Azurdia^{162,163}, K. Benstead^{164,165}, R. Twigger^{166,167}, K. Rieger^{168,169}, R. Brown^{170,171}, J.A. Sanches^{172,173}, D. Miyashiro^{174,175}, O. Akilov^{176,177}, S. McCann^{178,179}, H. Sahi^{180,181}, F.M. Damasco^{182,183}, C. Querfeld^{184,185}, A. Folkes^{186,187}, C. Bur^{188,189}, C.-D. Klemke^{190,191}, P. Enz^{192,193}, R. Pujol^{194,195}, K. Quint^{196,197}, L. Geskin^{198,199}, E. Hong^{200,201}, F. Evison^{202,203}, M. Vermeer^{204,205}, L. Cerroni^{206,207}, W. Kempf^{208,209}, Y. Kim^{210,211} and R. Willemze^{212,213}

¹European Co-ordinating PROCLIFI Centre for PROCLIFI, University Hospitals Birmingham, Birmingham, U.K.
²Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
³Member of the Cutaneous Lymphoma International Consortium (CLIC)
⁴Member of the UK Cutaneous Lymphoma Group

the PROCLIFI (PROspective International Cutaneous Lymphoma Prognostic Index) study for early-stage MF is a prototype study for international collaborations in rare disease and present our initial findings and central review process.

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study)


Running title: Treatment of early-stage Mycosis fungoides

P. Quaglino,¹ H.M. Prince,² R. Cowan,³ M. Vermeer,⁴ L. Papadavid,⁵ M. Bagot,⁶ O. Servitjie,⁷ E. Berti,⁸ E. Guenova,⁹ R. Stadler,¹⁰ C. Querfeld,¹¹ A.M. Busschots,¹² E. Hodak,¹³ A. Patsatsi,¹⁴ J. Sanches,¹⁵ M. Maule,¹⁶ J. Yoo,³¹ M. Kevin,³¹ P. Fava,¹ S. Ribero,¹ L. Zocchi,¹ M. Rubatto,¹ M.T. Fierro,¹ U. Wehkamp,¹⁷ M. Marshalko,¹⁸ C. Mitteldorf,¹⁹ O. Akilov,²⁰ P. Ortiz-Romero,²¹ T. Estrach,²² L. Vakeva,²³ P.A. Enz,²⁴ M. Wobser,²⁵ M. Bayne,²⁶ C. Jonak,²⁷ M. Rubeta,²⁸ A. Forbes,²⁹ A. Bates,³⁰ M. Battistella,⁶ R. Amel-Kashipaz,³¹ B. Vydianath,³¹ A. Combalia,²² E. Georgiou,¹⁴ E. Hauben,¹² E.K. Hong,³² M. Jost,²⁷ R. Knobler,²⁷ I. Amitay-Laish,¹³ D. Miyashiro,¹⁵ J. Cury-Martins,¹⁵ X. Martinez,¹¹ C. Muniesa,⁷ H. Prag-Naveh,¹³ V. Nikolaou,³ K. Quint,⁴ C. Ram-Wolff,⁹ K. Rieger,³² R. Stranzenbach,¹⁰ Á. Szepesi,¹⁸ S. Alberti-Violetti,⁸ E. Felicity,³¹ L. Cerroni,³³ W. Kempf,³⁴ S. Whittaker,³⁵ R. Willemze,⁴ Y. Kim³² and J.J. Scarisbrick^{31*}

Br J Dermatol . 2020 Jun 1. doi: 10.1111/bjd.19252. Online

Summary of treatments according to the therapy line

CORTESIA Prof. P. Quaglino



1st vs 2nd line

Chi square: 11,188

P<0.001

CTCLs are generally treated using a multimodal approach involving hematologists, dermatologists and radiation therapists.

Goals of therapy are to control symptoms, maintain cosmesis and improve survival by maximally reducing the tumor burden.


Maintenance treatments with skin directed or systemic therapy once remission has been achieved with the aim to maintain response and prevent relapse should be always considered particularly in advanced disease phases.

Critical concepts and management recommendations for cutaneous T-cell lymphoma: a consensus-based position paper from the Italian Group of Cutaneous Lymphoma

Pier Luigi Zinzani^{1,2}, Pietro Quaglino³, Silvia Alberti Violetti⁴, Maria Cantonetti⁵, Gaia Goteri⁶,
Francesco Onida⁷, Marco Paulli⁸, Serena Rupoli⁹, Giovanni Barosi¹⁰, Nicola Pimpinelli¹¹.

SKIN-DIRECTED THERAPIES

- Skin-directed therapy (SDT) should be considered for early stages of disease and at disease relapse with early lesions after CR in advanced stages.
- SDT associated with immunomodulating agents should be considered both for early stages refractory to/relapsing after SDT alone and for disease relapse with early lesions after CR in advanced stages.



Cutaneous Lymphoma Task Force

Gruppo Multidisciplinare LINFOMI CUTANEI Firenze

Vieri GRANDI, Irene LASTRUCCI, Isabella CIARDETTI, Marta BARZACCHI, *Pimpi*

Marco SANTUCCI, Vincenza MAIO, Raffaella SANTI (Anatomia Patologica)

Luca NASSI, Benedetta PUCCINI (Ematologia)

Gabriele SIMONTACCHI, Laura P. Ciccone (Radioterapia)

